Immunotherapy utilizing the adoptive transfer of lymphokine activated killer (LAK) cells in conjunction with recombinant interleukin-2 (IL-2) is capable of mediating the regression of established cancer in a variety of animal tumor models as well as advanced metastatic cancers in humans. We have thus examined the variability of the anti-tumor lytic reactivity of LAK cells obtained from patients with metastatic renal cell cancer (RCC). Tumor cell suspensions were prepared by enzymatic digestion from 37 consecutive renal cell tumors. The mean (+/- SEM) total number of cells recovered was 1.5 +/- 2.2 X 10(9) cells per tumor. The percentage of tumor cells in the suspension was 39.1 +/- 3.3% (range: 6 to 75%). Thirteen of 13 different fresh renal tumor cell preparations tested in 57 experiments and tow of two renal tumor lines tested in 10 experiments were all lysed by LAK cells. RCC patients, like normal donors, generated good LAK effectors with broad antitumor activity against autologous as well as allogenic tumors. Both renal and nonrenal tumors were equally lysed by LAK cells. LAK killing of the erythroleukemic tumor lines K562 and Daudi was significantly better than the lysis of fresh autologous and allogeneic tumor targets or cultured RCC tumor lines. Short term tumor cultures derived from renal cancer preparations proved to be sensitive and reliable tumor targets for studying the in vitro killing by LAK cells. Clinical trials testing the therapeutic role of LAK cells and IL-2 in patients with advanced renal cell cancer are currently in progress.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/s0022-5347(17)42342-1 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The functional role of LncRNA HOXA-AS2 in multiple human cancers.
Pathol Res Pract
December 2024
Research Fellow School of Life Sciences, University of Sussex, Brighton, UK. Electronic address:
Humans have more than 270,000 lncRNAs. Among these, lncRNA HOXA-AS2 is considered a transformative gene involved in various cellular processes, including cell proliferation, apoptosis, migration, and invasion. Thus, it can be regarded as a potential tumor marker for both diagnosis and prognosis.
View Article and Find Full Text PDFA3AR antagonism mitigates metabolic dysfunction-associated steatotic liver disease by exploiting monocyte-derived Kupffer cell necroptosis and inflammation resolution.
Metabolism
December 2024
College of Pharmacy and Medical Research Center, Chungbuk National University, Cheongju, Chungbuk, South Korea. Electronic address:
Article Synopsis
- This study focused on how the adenosine A3 receptor (A3AR) influences the progression of metabolic dysfunction-associated steatotic liver disease (MASLD) through the regulation of immune cells, particularly pro-inflammatory Kupffer cells derived from monocytes (MoKCs).
- Researchers found that inhibiting A3AR, either through a drug called FM101 or by genetic deletion, significantly improved liver inflammation and fibrosis in model mice.
- The results suggest that targeting A3AR may offer a novel therapeutic approach for treating MASLD by inducing cell death (necroptosis) in harmful immune cells, thereby promoting a healthier liver environment.
Leveraging Vγ9Vδ2 T cells against prostate cancer through a VHH-based PSMA-Vδ2 bispecific T cell engager.
iScience
December 2024
Department of Medical Oncology, Amsterdam UMC, Vrije Universiteit Amsterdam, Amsterdam 1081 HV, the Netherlands.
Vγ9Vδ2 T cells constitute a homogeneous effector T cell population that lyses tumors of different origin, including the prostate. We generated a bispecific T cell engager (bsTCE) to direct Vγ9Vδ2 T cells to PSMA prostate cancer (PCa) cells. The PSMA-Vδ2 bsTCE triggered healthy donor and PCa patient-derived Vγ9Vδ2 T cells to lyse PSMA PCa cell lines and patient-derived tumor cells while sparing normal prostate cells and enhanced Vγ9Vδ2 T cell antigen cross-presentation to CD8 T cells.
View Article and Find Full Text PDFThe future of cellular therapy for the treatment of renal cell carcinoma.
Expert Opin Biol Ther
November 2024
Interdisciplinary Department of Medicine, University of Bari "Aldo Moro", Bari, Italy.
Introduction: Systemic treatment options for renal cell carcinoma (RCC) have expanded considerably in recent years, and both tyrosine kinase inhibitors and immune checkpoint inhibitors, alone or in combination, have entered the clinical arena. Adoptive cell immunotherapies have recently revolutionized the treatment of cancer and hold the promise to further advance the treatment of RCC.
Areas Covered: In this review, we summarize the latest preclinical and clinical development in the field of adoptive cell immunotherapy for the treatment of RCC, focusing on lymphokine-activated killer (LAK) cells, cytokine-induced killer (CIK) cells, tumor-infiltrating T cells (TILs), TCR-engineered T cells, chimeric antigen receptor (CAR) T cells, and dendritic cell vaccination strategies.
Non-invasive measurement of wall shear stress in microfluidic chip for osteoblast cell culture using improved depth estimation of defocus particle tracking method.
Biomicrofluidics
September 2024
Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 111 Suwannabhumi Canal Rd, Bang Pla, Bang Phli District, Samut Prakan 10540, Thailand.
The development of a non-invasive method for measuring the internal fluid behavior and dynamics of microchannels in microfluidics poses critical challenges to biological research, such as understanding the impact of wall shear stress (WSS) in the growth of a bone-forming osteoblast. This study used the General Defocus Particle Tracking (GDPT) technique to develop a non-invasive method for quantifying the fluid velocity profile and calculated the WSS within a microfluidic chip. The GDPT estimates particle motion in a three-dimensional space by analyzing two-dimensional images and video captured using a single camera.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!